Medison Ventures

About

Portfolio · 2

DermaDetect

AI-driven Digital Diagnostics for Skin Disorders

1 round $1.9M committed Latest: 2022-03

Alpha Tau Medical

Cancer Radiotherapy

2 rounds $55.0M committed Latest: 2020-06

Investment activity

1 portfolio exit on record.

Q&A

What is Medison Ventures' primary investment focus?

Medison Ventures, the corporate venture arm of Medison, focuses on in-licensing, investments, and scouting for breakthrough technologies in biotech and digital health.

Which investment stages does Medison Ventures typically engage in?

Medison Ventures invests across various stages, including Pre-Seed, Seed, A Round, B Round, C Round, D Round, E Round, and F Round.

Can you name a notable exit for Medison Ventures?

Medison Ventures saw an exit in March 2022 when its portfolio company, Alpha Tau Medical, went public via a SPAC event with Healthcare Capital Corp on NASDAQ, raising $90M.

What is the sector concentration of Medison Ventures' portfolio?

Medison Ventures' portfolio is concentrated in the Health Tech & Life Sciences sector, with all two of its listed portfolio companies falling into this category.

Who are the key personnel at Medison Ventures?

Gil Gurfinkel serves as a Managing Partner, and Dr. Yael Grunbaum-Cohen is a Director at Medison Ventures.

Which company in Medison Ventures' portfolio is focused on AI-driven diagnostics for skin disorders?

DermaDetect, a Medison Ventures portfolio company, specializes in AI-driven digital diagnostics for skin disorders.

When was Medison Ventures founded?

Medison Ventures was founded in 2016.